AWM Investment Company Inc. Has $13.82 Million Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

AWM Investment Company Inc. lessened its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 9.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,000 shares of the medical instruments supplier's stock after selling 15,000 shares during the quarter. LeMaitre Vascular comprises about 1.7% of AWM Investment Company Inc.'s investment portfolio, making the stock its 26th biggest position. AWM Investment Company Inc. owned about 0.67% of LeMaitre Vascular worth $13,821,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of LMAT. Smartleaf Asset Management LLC boosted its holdings in LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 293 shares during the period. CBIZ Investment Advisory Services LLC lifted its position in shares of LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 117 shares during the last quarter. KBC Group NV boosted its stake in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after purchasing an additional 410 shares during the period. Huntington National Bank boosted its stake in LeMaitre Vascular by 64.9% during the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after purchasing an additional 455 shares during the period. Finally, Empowered Funds LLC acquired a new stake in LeMaitre Vascular in the 4th quarter valued at approximately $150,000. Institutional investors own 84.64% of the company's stock.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now owns 5,564 shares in the company, valued at $456,915.68. The trade was a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO George W. Lemaitre sold 18,733 shares of LeMaitre Vascular stock in a transaction on Friday, May 16th. The stock was sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the sale, the chief executive officer now owns 1,873,651 shares in the company, valued at $158,829,395.27. This represents a 0.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 102,009 shares of company stock worth $8,721,836 over the last 90 days. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Price Performance

LMAT stock traded up $2.28 on Friday, reaching $81.40. 205,755 shares of the company were exchanged, compared to its average volume of 166,624. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The stock's fifty day moving average price is $84.19 and its 200 day moving average price is $92.47. The firm has a market capitalization of $1.84 billion, a PE ratio of 44.48, a PEG ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. During the same period last year, the firm posted $0.44 EPS. The company's revenue was up 12.0% compared to the same quarter last year. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. LeMaitre Vascular's dividend payout ratio is currently 40.40%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LMAT. Lake Street Capital upped their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price on the stock. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, LeMaitre Vascular presently has an average rating of "Moderate Buy" and a consensus price target of $98.14.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.